Marker Therapeutics, Inc. stock is down -5.9% since 30 days ago. The next earnings date is Mar 20, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 30.77% of the previous 25 December’s closed higher than November.
Marker Therapeutics, Inc. engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors. It is also developing TPIV100/110 and TPIV200, which is in Phase 2 clinical trials for breast and ovarian cancers.